Kisho

Infinity Pharmaceuticals, Inc. — Rare Disease Pipeline | Kisho | Kisho

Infinity Pharmaceuticals, Inc.

Other

Orphan Designations

FDA Approvals

Rare Diseases

News Articles

Disease	Drug(s)	Designation	Approved
carbon monoxide-induced delayed encephalopathy	oral potent and selective antagonist	Orphan Designation	-
malignant carotid body paraganglioma	retaspimycin	Orphan Designation	-
multisystemic smooth muscle dysfunction syndrome	oral potent and selective antagonist	Orphan Designation	-
natal teeth-intestinal pseudoobstruction-patent ductus syndrome	oral potent and selective antagonist	Orphan Designation	-
post-treatment Lyme disease syndrome	retaspimycin	Orphan Designation	-
treatment-refractory schizophrenia	retaspimycin	Orphan Designation	-